GSK Securities Class Action: GSK PLC Investors Should Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the GSK Class Action Lawsuit

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of purchasers of GSK PLC's American Depository Receipts (ADRs) due to allegations of misleading investors regarding the recall of Zantac [1][2] Allegations and Legal Context - GSK suspended the distribution of Zantac and initiated a voluntary recall in September and October 2019, following which the FDA requested a halt on sales of Zantac and its generics [2] - The complaint claims that GSK misrepresented the reasons for the recall and concealed data linking ranitidine to cancer, which could implicate the company's liability [2] - Following the recall, numerous personal injury and product liability lawsuits were filed against GSK by cancer-stricken patients [3] Financial Implications - A Deutsche Bank report on August 10, 2022, suggested that GSK and other distributors might face shared liability, estimating total litigation liability between $5 billion and$10 billion, which led to a decline of over 10% in GSK ADRs [4] - On August 15, 2022, GSK acknowledged potential liability exposure of $1 billion to$10 billion, with a final settlement of $2.2 billion falling within this range, causing an additional 3% decline in ADRs [5] Class Action Participation - Shareholders interested in participating as lead plaintiffs must file by April 7, 2025, but can remain absent class members without taking action [6]